Harbinger Capital Sells $104.6M Worth of Calpine
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
10:08AM 12/11/09
09:00AM 12/01/09
Vanda's Fanapt Deal Just Okay: BioBuzz
Bulls were hoping for a Vanda takeover.
09:54AM 10/13/09
Novartis to Market Vanda's Fanapt Drug
Vanda Pharmaceuticals entered into an exclusive license agreement with Novartis to commercialize and develop schizophrenia drug Fanapt in the U.S. and Canada.
02:01AM 10/13/09
Novartis, Vanda In Drug Deal Worth Up To $265M
Novartis to pay Vanda up to $465 million for rights to sell schizophrenia drug in US, Canada
07:01PM 10/12/09
By Alix Steel | By Adam Feuerstein
From the Best of TSC TV: BOSTON (TheStreet) - Adam Feuerstein, senior biotech reporter, talks swine flu, small cap stock, healthcare reform, speculative stocks and Dendreon. Watch this video to see Adam's top biotech stock picks. original air date: 09/29/2009.
05:00PM 10/04/09
By Alix Steel | By Adam Feuerstein
BOSTON (TheStreet) -- Adam Feuerstein, senior biotech reporter, breaks down the biotech stocks you want to know about and how to trade them.
12:00PM 10/02/09
By Alix Steel | By Adam Feuerstein
BOSTON (TheStreet) - Adam Feuerstein, senior biotech reporter, talks swine flu, small cap stock, healthcare reform, speculative stocks and Dendreon. Watch this video to see Adam's top biotech stock picks.
02:12PM 09/29/09
Bullish Case for Vanda Loses Steam
Vanda's chances of getting acquired seem to be drying up, according to two analysts.
01:37PM 09/15/09
Biotech Stock Mailbag: Genta Takes Another Stab
Readers weigh in on Genta, Opexa, Osiris, Vivus and Antigenics.
07:00AM 09/11/09
Weighing Arena's Obesity Drug: Biotech Mailbag
Readers weigh in on Arena Pharmaceuticals' obesity drug, Affymax's stock, and Cell Therapeutics' pixantrone.
07:00AM 09/04/09
Today's meandering market could be a pause, or it could be the start of something more.
01:16PM 08/26/09
Vanda, Oculus, Sequenom: Biotech Notebook
Vanda Pharmaceuticals can't find a buyout partner; Oculus Innovative Sciences backs off drug claims; Sequenom walks back expectations for its Downs syndrome gene test.
07:00AM 08/11/09
A Tough Stretch (RealMoney.com $)
Earnings reports will prevent both bears and bulls from being too aggressive.
11:03AM 07/16/09
Despite Positive Reversal, Still Hesitant (RealMoney.com $)
Emotions are high and we risk more big swings with pending earnings reports.
11:21AM 07/13/09
Connect with TheStreet